Hygieia Bio Secures Tens of Millions in Series A2 Financing to Advance siRNA Pipeline into Clinical Development

Sep 03, 2024 10:36 CST Updated 10:36

Hygieia

Small Interfering RNA (siRNA) Drug Developer

▎WuXi AppTec Content Team Report

Today (September 3rd),Hygieia Bio（Hygieia ）Announced that it has been completed recentlyTens of Millions of RMB in A2 Round Financing，Led by Huangpu Biomedical Fund, with Nanwan Biofund following up.。Meanwhile,Hygieia Pharmaceuticals Co., Ltd.'s A+ Round FinancingSynchronization in progress, plannedFor multiple Phase 1 clinical trialsPipeline development supplementary funds for the period, toAndTo provide financial support for the development of more IND-enabling stage projects and to further the early-stage research of extrahepatic delivery platform technology.

Public information shows that Hygieia is committed to the construction of a delivery technology platform in the siRNA field and drug development. The company has established an end-to-end siRNA drug development platform from target discovery to clinical proof-of-concept.Focusing on disease areas with urgent clinical needs or no available treatments. Its pipeline covers hepatitis B, NASH/MASH, cardiovascular and metabolic diseases, complement-mediated diseases, and neurological disorders.

According to a press release from Hygieia, the companyAuthorized to Fosun Pharma's Starry KunzeTreatment of Chronic Hepatitis B Virus InfectionsiRNADrug, have respectively received NMPA and FDA approval to enter clinical trials. The results of each phase of the drug's Phase 1 clinical study demonstrated good safety, tolerability, and therapeutic potential.

Another product developed by the company forPipeline for the Treatment of Hyperlipoproteinemia (a)Kylo-11 is currently in Phase 1 clinical research. Preliminary clinical data of this investigational product has shown promising efficacy and safety, with the potential to play a therapeutic role in reducing the risk of cardiovascular and cerebrovascular diseases in the future.

In addition, the company'sDual-targeting Liver THRβ Agonist PipelineKylo-0603 can minimize the systemic exposure of THRβ agonists, reducing side effects on extrahepatic organs (such as the heart and thyroid axis). Preclinical efficacy studies have shown that this pipeline not only significantly improves NAS scores and reverses liver fibrosis but also notably promotes energy metabolism. Currently, this pipeline has completed all follow-ups for Phase 1 clinical trials. Preliminary results indicate that in healthy subjects, 14 days of continuous administration achieves key metrics such as a more significant reduction in LDL-C compared to similar drugs, with good safety and tolerability.

References:

[1] Hygieia Completes A2 Financing Round, Rapidly Advancing Multiple siRNA Pipeline Clinical Developments. Retrieved Sep 3， 2024, from https://mp.weixin.qq.com/s/zXToKKx3llRODS2KLd4iuA

This article was compiled and edited by the WuXi AppTec content team based on publicly available information. Feel free to share it on your personal social media feed. For reprint authorization or other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.